In the MSKCC Phase 1 trial, autologous CD19-targeted CAR T cells expressing the second-generation CAR (19-28z) were evaluated for their safety and persistence in treating relapsed or chemotherapy refractory CLL and B-ALL. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.